key: cord-0916251-aqr47tlg
authors: Meyers, Kristin J.; Dillman, Brian; Williams, Charles; Jiang, Jianfei; Clifford, Nancy; Miller, Jennifer L.; Jones, Meghan E.; Goetz, Iris A.; Botros, Fady T.; Knorr, Jack; Manner, David H.; Woodward, Brad
title: Follow‐up of SARS‐CoV‐2 positive subgroup from the Asymptomatic novel CORonavirus iNFection study
date: 2021-02-01
journal: J Med Virol
DOI: 10.1002/jmv.26810
sha: d0a6d6fdc155f544d6984f8d9e5c66e37d20242b
doc_id: 916251
cord_uid: aqr47tlg

A nested longitudinal study within theAsymptomatic novel CORonavirus iNFfection study followed participants with positive nasopharyngeal swab to query for development of symptoms and assess duration of positive reverse transcription‐polymerase chain reaction (RT‐PCR) test results. Of the 91 participants initially testing positive, 86 participated in follow‐up approximately 14 days after study enrollment; of those 86 participants, 19 (22.1%) developed at least one symptom at any time after the initial positive severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) test result. The median number of days to symptom development after their initial positive test result was 6 (range 1–29 days). No participants reported a SARS‐CoV‐2‐related hospitalization. The most frequently reported symptoms were fatigue or muscle aches (10.5%), headache (9.3%), fever (5.8%), and shortness of breath (5.8%). Of the 78 participants who submitted a nasopharyngeal swab for repeat RT‐PCR testing, 17 (21.8%) remained positive at Day 14, 4 of which continued to test positive at Day 28. These findings reinforce the probable role of silent SARS‐CoV‐2 infections in community transmission, and that reliance on symptom development will miss a large proportion of infections. Broad testing programs not limited to individuals presenting with symptoms are critical for identifying persons with SARS‐CoV‐2 infection and ultimately slowing transmission.

infections originate from individuals without symptoms at the time of transmission, this includes individuals who are presymptomatic and those who will remain asymptomatic over the course of their infection. 8 Despite the now well-documented asymptomatic proportion of infection and infectivity of asymptomatic infections, there is a dearth of longitudinal studies documenting the clinical experience of initially asymptomatic infections. A narrative review of studies of asymptomatic SARS-CoV-2 infections noted that in four of five studies with longitudinal data (of variable length), only a fraction of persons originally asymptomatic subsequently developed symptoms. 9 A better understanding of asymptomatic infections is a critical knowledge gap and an increasing point of interest in curbing the pandemic.

The Asymptomatic novel CORonavirus iNFection (ACORN) study was designed to study the prevalence of SARS-CoV-2 infection in asymptomatic adults of the Indianapolis metropolitan area over a 6-week period between April 7 and May 9, 2020. Over this period, 91 of 2953 individuals (3.1%) initially presenting as asymptomatic for coronavirus disease 2019 (COVID-19) based on the absence of new or worsening cough, new or worsening shortness of breath, or fever in 7 days prior tested positive for SARS-CoV-2. 10 In an effort to better understand the course of infection in these initially asymptomatic infections, participants were followed to inquire for the development of symptoms, and investigate the duration of positive test results by repeat nasopharyngeal swabs. Interim results have been previously reported for 81 of the SARS-CoV-2 positive participants. 10 Here we report the final results from the ACORN observational study, with an emphasis on the longitudinal follow-up of initially asymptomatic participants testing positive for SARS-CoV-2.

ACORN is a cross-sectional, community-based, observational study of adults presenting asymptomatic for COVID-like illness, with a nested longitudinal study for participants that test positive. Asymptomatic upon study enrollment was defined as the self-reported absence of fever (≥100°F), new onset or worsening cough, and new onset or worsening of shortness of breath within the previous week.

Study design, patient eligibility, and statistical analysis have been previously reported. 10 Briefly, nasopharyngeal swabs were collected in-person by trained personnel at a drive-through testing facility. Test results were available within 1-3 days of sample collection. Those who tested positive were contacted by trained medical professionals approximately 14 days after the sample resulting in a positive test was collected and given a structured questionnaire to query symptom development since the time of the test. Symptoms specifically queried were as follows: fever, cough, shortness of breath, chills, fatigue or muscle aches, sore throat, headache, GI symptoms, loss of smell or taste. If symptoms were reported, date of first symptom onset was asked.

Severity of symptoms was not queried. Participants were asked if they had been hospitalized for COVID-related reasons. Open report of other symptoms was allowed. Additionally, during the follow-up contact querying symptom development, the participant was invited to return for a repeat reverse transcription-polymerase chain reaction (RT-PCR) test.

A maximum of 3 repeat nasopharyngeal swabs at approximately 2-week intervals from initial test were offered until the result was negative. As such, the study activities (i.e., RT-PCR testing and follow-up telephone call, if positive) were repeated at 14-day intervals for anyone consenting to participate in repeat testing until the participant either tested negative, completed three repeat tests, or was lost to follow-up.

The study protocol (including the protocol addendum for repeat testing) was approved by an external IRB (WIRB-Copernicus) and performed in compliance with relevant regulations and in accordance with the ethical standards of the Declaration of Helsinki. All participants provided informed consent.

Specimens were collected at a drive-through testing facility by 

As previously reported, 10 91 of 2953 participants asymptomatic for SARS-CoV-2 tested positive initially over the 6-week period of study enrollment (3.1%; 95% confidence interval, 2.5%-3.7%). The weekly point prevalence was generally consistent over the course of the 6 weeks ( Figure 1 ).

An analysis was conducted to assess the sensitivity of the prevalence estimate to the definition of "asymptomatic," which was absent new or worsening fever, cough, or shortness of breath in the 7 days before enrollment. There were a total of 492 participants that reported at least one other baseline symptom (either chills, fatigue or muscle aches, sore throat, headache, GI symptoms, or loss of smell or taste), among which 13 (N = 91; 14.3%) tested positive and 479 (N = 2862; 16.7%) tested negative. 10 In an analysis removing all 492 participants reporting any other symptom at study enrollment, the prevalence of SARS-CoV-2 infection remained consistent at 3.2% (78 of 2461 participants).

Demographics and health characteristics for the participants of the ACORN study were previously published. 10 In summary, the average age of the overall study cohort was 49.6 years old (range 18-88), 58.9% female, and 89.8% White. When qualitatively comparing those participants testing positive to the overall sample, participants positive for SARS-CoV-2 were slightly younger (aver- There is a need to better understand transmission of the virus from those with SARS-CoV-2 who remain asymptomatic or become mildly symptomatic. A recognized limitation of RT-PCR is that the test will identify virus over the course of an infection, including after a person is infectious. However, the window for transmission of the virus to another person is not known. A recent review noted that asymptomatic persons can transmit SARS-CoV-2 for an extended period, perhaps longer than 14 days. 9 While there are reports correlating transmission potential with higher viral loads (i.e., low C t values), SARS-CoV-2 has also been cultured from persons with low viral loads. 16, 17 There are two noted limitations to the classification of "asymp- during the enrollment questionnaire. 10 The prevalence estimate among an asymptomatic cohort was not sensitive to these definitions of "asymptomatic" and the minimal reporting of symptom development in baseline suggests that neither of these limitations influenced the presented estimate of prevalence within an asymptomatic cohort. Employees of the sponsor could participate in the study, but participation was optional and capped.

The COVID-19 pandemic: a comprehensive review of Taxonomy, genetics, epidemiology, diagnosis, treatment, and control

Centers for Disease Control and Prevention. Cases and deaths in the U.S. coronavirus disease 2019

Presumed asymptomatic carrier transmission of COVID-19

Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'

Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship

Transmission of 2019-nCoV Infection from an asymptomatic contact in Germany

IUPI, ISDH release findings from phase 2 of COVID-19 testing in Indiana Health and Wellness

SARS-CoV-2 transmission from people without COVID-19 symptoms

Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review

A cross-sectional communitybased observational study of asymptomatic SARS-CoV-2 prevalence in the greater Indianapolis area

Influenza specimen collection

Centers for Disease Control and Prevention. CDC 2019-novel coronavirus (2019-nCoV) real-time RT-PCR diagnostic panel. 2020

Three quarters of people with SARS-CoV-2 Infection are asymptomatic: analysis of English household survey data

SARS-CoV-2 Infections and serologic responses from a sample of U.S. vavy service members-USS Theodore Roosevelt

Theodore Roosevelt sailors re-test positive for coronavirus. NavyTimes

Persistent SARS-CoV-2 replication in severe COVID-19. medRxiv

From more testing to smart testing: data-guided SARS-CoV-2 testing choices. medRxiv. 2020. 18. Centers fro Disease Control Prevention. Symptoms of coronavirus

Follow-up of SARS-CoV-2 positive subgroup from the asymptomatic novel coronavirus infection study

All authors are employees and shareholders of Eli Lilly and Company.

All authors participated in the drafting and critical revision of the manuscript. All authors approved the final submitted version of the manuscript.

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

http://orcid.org/0000-0002-4329-5115